BioMarin Pharmaceutical Inc. Doses First Patient In Phase 2 Trial With BMN 111 For The Treatment Of Children With Achondroplasia

Published: Jan 14, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN RAFAEL, Calif., Jan. 14, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first child in the Phase 2 trial with BMN 111, an analog of C-type Natriuretic Peptide (CNP), for the treatment of children with achondroplasia. Achondroplasia is the most common form of disproportionate short stature or dwarfism.

Help employers find you! Check out all the jobs and post your resume.

Back to news